Nirmatrelvir + Ritonavir

Nirmatrelvir + Ritonavir indicated for mild-to-moderate COVID-19 positive adult and pediatric patients (12 years of age and older weighing at least 40 kg), who are at high risk for progression to severe COVID-19, including hospitalization or death.

Antiviral

This inhibits the main protease (Mpro) of the SARS-CoV-2. This main protease (Mpro) is also referred as 3C-like protease (3CLpro) or nsp5 protease. This inhibition of Mpro hampers the peptidomimetic activity of SARS-CoV-2. Ritonavir is an HIV-1 protease inhibitor but is not active against SARS-CoV-2 Mpro. Ritonavir inhibits the CYP3A mediated metabolism of Nirmatrelvir, resulting in increased plasma concentrations of Nirmatrelvir

Take 2 tablets of nirmatrelvir with 1 tablet of ritonavir by mouth 2 times each day (in the morning and in the evening) for 5 days. For each dose, take all 3 tablets at the same time

If you have kidney disease, talk to your healthcare provider. You may need a different dose

Co-administration of this tablet with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated. Co-administration with other CYP3A substrates may require a dose adjustment or additional monitoring. Nirmatrelvir and Ritonavir are CYP3A substrates; therefore, drugs that induce CYP3A may decrease Nirmatrelvir and Ritonavir plasma concentrations and reduce this tablet therapeutic effect.

History of clinically significant hypersensitivity reactions to the active ingredients (Nirmatrelvir or Ritonavir) or any other components

Co-administration with drugs highly dependent on CYP3A for clearance and for which elevated concentrations are associated with serious and/or life-threatening reactions

Adverse events (incidence ≥1% and ≥5 subject difference) were dysgeusia, diarrhea, hypertension, and myalgia.

There is no experience treating pregnant women or breastfeeding mothers with Bexovid. For a mother and unborn baby, the benefit of taking Bexovid may be greater than the risk from the treatment. If someone is pregnant, discuss the specific situation with healthcare provider.

If someone is breastfeeding, discuss the options and specific situation with healthcare provider.

Treatment of an overdose of this tablet should consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. There is no specific antidote for overdose with this tablet.

Do not store above 30° C. Keep in a dry place. Protect from light and keep out of the reach of children.

As per Physician

Each combipack contains- 4 Nirmatrelvir Tablets (each tablet contains Nirmatrelvir INN 150 mg) and 2 Ritonavir Tablets (each tablet contains Ritonavir USP 100 mg)